All In Biotech

Drug Trial Radar · NCT02974855

PF-06741086 Multiple Dose Study in Severe Hemophilia

A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA

Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

27

Actual

Start

Mar 8, 2017

Primary completion

Dec 3, 2018

Study completion Dec 3, 2018

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.

Conditions

  • Hemophilia A or B

Interventions

  • PF-06741086Biological

    PF-06741086 subcutaneous (SC) injection

  • PF-06741086Biological

    PF-06741086 SC injection

  • PF-06741086Biological

    PF-06741086 SC injection

  • PF-06741086Biological

    PF-06741086 SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Study Day 1 to Day 113 Visit
  2. Number of Participants Discontinued From Study Due to TEAEsTime frame: Study Day 1 to Day 113 Visit
  3. Number of Participants With Abnormal Laboratory Findings-HematologyTime frame: Baseline to Study Day 113 Visit
  4. Number of Participants With Abnormal Laboratory Findings-Clinical ChemistryTime frame: Baseline to Study Day 113
  5. Number of Participants With Abnormal Laboratory Findings-UrinalysisTime frame: Baseline to Study Day 113 Visit
  6. Change From Baseline for Globulin by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
  7. Change From Baseline for Prothrombin International Normalized Ratio (PT/INR) by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
  8. Change From Baseline for Activated Partial Thromboplastin Time (aPTT) by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
  9. Change From Baseline for Fibrinogen by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57, 85 and 113.
  10. Change From Baseline for Antithrombin III by Dose CohortTime frame: Baseline, Study Day 8, 15, 22 and 29.
  11. Change From Baseline for Troponin I by Dose CohortTime frame: Baseline, Study Day 8, 15, 22, 29, 57 and 85.
  12. Number of Participants With Vital Signs Data Meeting Pre-specified CriteriaTime frame: Baseline to Study Day 113 Visit
  13. Number of Participants With Electrocardiogram (ECG) Change Meeting Pre-specified CriteriaTime frame: Baseline to Study Day 29 Visit.
  14. Number of Participants With Clinically Significant Changes in Physical Examination FindingsTime frame: Baseline to Study Day 113 Visit
  15. Number of Participants With Infusion and Injection Site ReactionsTime frame: Baseline to Study Day 113 Visit

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • UC Denver Hemophilia and Thrombosis Center - Pharmacy

    Aurora, Colorado

  • UC Denver Hemophilia and Thrombosis Center

    Aurora, Colorado

  • Pharmacy

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Hospital Dr. Sotero del Rio

    Santiago, Chile

  • Klinicki bolnicki centar Zagreb

    Zagreb, Croatia

  • Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Phoenix Pharma (Pty) Ltd

    Port Elizabeth, Eastern Cape, South Africa

  • Haemophilia Comprehensive Care Centre

    Johannesburg, Gauteng, South Africa

  • UniversitatsSpital Zurich, Klinik fur Hamatologie

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.